PNV Media Thread, page-1212

https://www.mdpi.com/1010-660X/57/3/225/htm

Worth a read

MatriDerm^®, a dermal, cell-free skin substitute for deep-seated burns, has been commercially available for several years. The matrix consists of bovine collagen type I, collagen type III and elastin. As studied in animal models, MatriDerm^® matrix is converted into endogenous matrix by the recipient organism over a period of weeks [71,77]. Similar biodegradable behavior has also been demonstrated in the human organism [78]. MatriDerm^® is available in various thicknesses and can be stored at room temperature, making handling considerably easier than with other biomaterials [71]. In particular, the single-stage procedure with simultaneous autologous split-thickness skin grafting is clinically considered a significant advantage and showed no inferiority to allogeneic split-thickness skin grafting alone [3]. Better scar quality as well as reduced wound contraction were observed [79,80], so the results to date in clinical application are promising [80,81]. However, full-thickness skin replacement with MatriDerm^® is so far only possible in combination with autologous split-thickness skin grafting.

NovoSorb^® BTM is a fully synthetic dermal skin substitute that eliminates any risks of cross-species residual antigenicity. It consists of biodegradable polyurethane foam with a temporary non-biodegradable polyurethane seal. Thereby, it is easy and inexpensive to produce [76]. A further advantage is the avoidance of cross-species immune rejection or disease transmission as well as circumventing ethical and cultural objections to the use of animal derived products. A plethora of proof-of-concept studies using NovoSorb^® BTM has been conducted to determine its safety and ability to provide permanent wound closure when combined with split-thickness skin grafts in a two-stage procedure in sheep, pigs and humans [82,83]. Furthermore, the particular abundance of host inflammatory cells in athymic nude mice receiving full-thickness skin excision followed by grafting of the dermal NovoSorb^® BTM template, showed evidence that new collagen deposition and neovascularization with BTM had a more extensive vascular network compared to Integra^® (Integra LifeSciences, Plainsboro, NJ, USA) [84]. NovoSorb^® BTM demonstrates favorable properties as dermal skin substitute but further studies are needed to evaluate its position in clinical routine, especially for the treatment of burns.